Avenue Therapeutics' AJ201: A Buy Rating for Innovative SBMA Treatment and Promising Clinical Progress
TipRanksApr 3 19:05
Buy Rating Affirmed for Avenue Therapeutics Amid Strong Prospects for IV Tramadol and Strategic Growth Potential
TipRanksFeb 1 20:37
Analysts Conflicted on These Healthcare Names: Avenue Therapeutics (ATXI) and Inovio Pharmaceuticals (INO)
TipRanksJan 4 01:20
Maxim Group Initiates Coverage On Avenue Therapeutics With Buy Rating, Announces Price Target of $0.75
BenzingaDec 11, 2023 22:43
Avenue Therapeutics Analyst Ratings
BenzingaDec 11, 2023 22:38
Aegis Capital Initiates Coverage On Avenue Therapeutics With Buy Rating, Announces Price Target of $32
BenzingaApr 4, 2023 01:35
No Data
No Data